lipustobart (LZM009) / Livzon Pharma - LARVOL DELTA

"#BrightPeakTherapeutics Licenses Rights to #Livzons #AntiPD1 #Antibody #LZM009 to Develop Novel #PD1 Targeted #Immunocytokines https://t.co/FIHSorbxHm" (@1stOncology)

Bright Peak Therapeutics Licenses Rights to Livzon’s Anti-PD-1 Antibody LZM009 to Develop Novel PD-1 Targeted Immunocytokines (GlobeNewswire) - "Bright Peak Therapeutics...announced that it has entered into a license agreement with Livzon Mabpharm...to use LZM009, Livzon’s proprietary anti-PD-1 monoclonal antibody currently in late-stage clinical trials, to develop novel PD-1 targeted immunocytokines ('PD-1 ICs'). The PD-1 ICs will be comprised of optimized cytokine payloads developed by Bright Peak conjugated to LZM009 for the treatment of a variety of cancers....Under the terms of the license agreement, Bright Peak will receive the right to develop, manufacture and commercialize PD-1 ICs on a worldwide basis while Livzon retains certain rights of first negotiation to obtain exclusivity in the greater China territory."

Licensing / partnership • Oncology

LZM009 to Treat Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1; N=30; Completed; Sponsor: Livzon Pharmaceutical Group Inc.; Recruiting ➔ Completed; Trial completion date: Jan 2019 ➔ Apr 2019

Clinical • Trial completion • Trial completion date